Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

PellePharm, Inc.

http://www.pellepharm.com

Latest From PellePharm, Inc.

BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach

The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.

Business Strategies Rare Diseases

Leo Sets Up For A David & Goliath Showdown In Atopic Dermatitis

Scrip talked to Leo Pharma's new CEO Catherine Mazzacco about going up against big biopharma players in dermatology and plans to file tralokinumab in 2020.

Dermatology Business Strategies

Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals

A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.

Deals Financing

BridgeBio’s $299m Gives It Two More Years Of Runway To Launch New Companies

The company emerged in 2017 with $135m to spin out rare genetic disease-focused subsidiaries. Now with 18 start-ups and two near-term filings for drug approvals, BridgeBio will fund existing programs as they progress and continue to buy new assets.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • BridgeBio Pharma
UsernamePublicRestriction

Register